Boston Scientific to present data for wide range of products at TCT


Key data presentations spanning Boston Scientific’s broad interventional cardiology, structural heart and peripheral interventions portfolios will be shared at the Transcatheter Cardiovascular Therapeutics (TCT) meeting (11–15 October, San Francisco, USA), the company has revealed. The scheduled abstracts will evaluate Boston Scientific technologies for treating patients with a range of cardiovascular diseases.

A Boston Scientific press release reports that these abstracts will cover: the costs associated with bleeding complications due to warfarin versus the Watchman left strial sppendage closure device, which was approved by the FDA in March, 2015 to reduce the risk of stroke in people with non-valvular atrial fibrillation; Lotus transcatheter aortic valve implantation (TAVI) system safety and efficacy data from the REPRISE I and REPRISE II studies; and long-term safety and efficacy data out to five years with the Promus Element platinum chromium everolimus-eluting stent.

Earlier this week, the company received FDA approval of the Synergy Bioabsorbable Polymer drug-eluting stent system for the treatment of patients with coronary artery disease.

Keith Dawkins, global chief medical officer, Boston Scientific, says: “The recently approved and first-to-market Watchman device and Synergy stent are opening doors for cardiologists to treat patients with non-valvular atrial fibrillation and coronary artery disease in new and innovative ways. In addition to exploring these prevalent health conditions at TCT, we will also share data crucial to the advancement of device-related treatment for patients suffering from aortic valve disease and peripheral arterial disease.”

Abstract schedule:

11 October—1–1.13pm; Moscone West, 3rd Floor, Rooms 3001–05

Everolimus-eluting bioabsorbable-polymer drug-eluting stent outcomes: Synergy update:

13 October—3pm; Rooms 3014–18

Two-year outcomes in “real-world patients” treated with a thin-strut, platinum-chromium, everolimus-eluting stent, in the Promus Element Plus US post-approval study

13 October—3.30pm; location TBC

Cost analysis of bleed complications from two stroke prevention strategies in non-valvular atrial fibrillation: left atrial appendage

15 October—12.45pm; Room Moscone South, Lower Level, Room 104

Two-year outcomes with the fully repositionable and retrievable Lotus transcatheter aortic replacement valve in 120 high-risk surgical patients with severe aortic stenosis: Results from the REPRISE II CE-mark study

For additional product information, visit Boston Scientific at booth #1225.